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Association of Hydroxylmethyl Glutaryl Coenzyme A
Reductase Inhibitors, L-Type Calcium Channel Antagonists,
and BiguanidesWith Rates of Psychiatric Hospitalization
and Self-Harm in IndividualsWith SeriousMental Illness
Joseph F. Hayes, PhD; Andreas Lundin, PhD; SusanneWicks, PhD; Glyn Lewis, PhD; Ian C. K. Wong, PhD;
David P. J. Osborn, PhD; Christina Dalman, PhD
IMPORTANCE Drug repurposing is potentially cost-effective, low risk, and necessary in
psychiatric drug development. The availability of large, routine data sets provides the
opportunity to evaluate the potential for currently usedmedication to benefit people
with serious mental illness (SMI).
OBJECTIVE To determine whether hydroxylmethyl glutaryl coenzyme A reductase inhibitors
(HMG-CoA RIs), L-type calcium channel (LTCC) antagonists, and biguanides are associated
with reduced psychiatric hospitalization and self-harm in individuals with SMI.
DESIGN, SETTING, AND PARTICIPANTS Thesewithin-individual cohort studies of patients with
SMI compared rates of psychiatric hospitalization and self-harm during periods of exposure
and nonexposure to the study drugs, with adjusting for a number of time-varying covariates.
Participants included 142 691 individuals from the entire population of Sweden with a
diagnosis of bipolar disorder (BPD), schizophrenia, or nonaffective psychosis (NAP) whowere
15 years or older and whowere treated with psychiatric medication fromOctober 1, 2005,
through December 31, 2016. Data were analyzed from April 1 through August 31, 2018.
INTERVENTIONS Treatment with HMG-CoA RIs, LTCC antagonists, or biguanides.
MAIN OUTCOMES ANDMEASURES Psychiatric hospitalizations and self-harm admissions.
RESULTS Among the 142 691 eligible participants, the HMG-CoA RI exposure periods were
associated with reduced rates of psychiatric hospitalization in BPD (adjusted hazard ratio
[aHR], 0.86; 95% CI, 0.83-0.89; P < .001), schizophrenia (aHR, 0.75; 95% CI, 0.71-0.79;
P < .001), and NAP (aHR, 0.80; 95% CI, 0.75-0.85; P < .001) and reduced self-harm rates in
BPD (aHR, 0.76; 95% CI, 0.66-0.86; P < .001) and schizophrenia (aHR, 0.58; 95% CI,
0.45-0.74; P < .001). Exposure to LTCC antagonists was associated with reduced rates of
psychiatric hospitalization and self-harm in subgroups with BPD (aHRs, 0.92 [95% CI,
0.88-0.96; P < .001] and 0.81 [95% CI, 0.68-0.95; P = .01], respectively), schizophrenia
(aHRs, 0.80 [95% CI, 0.74-0.85; P < .001] and 0.30 [95% CI, 0.18-0.48; P < .001],
respectively), and NAP (aHRs, 0.89 [95% CI, 0.83-0.96; P = .002] and 0.56 [95% CI,
0.42-0.74; P < .001], respectively). During biguanide exposure, psychiatric hospitalization
rates were reduced in subgroups with BPD (aHR, 0.80; 95% CI, 0.77-0.84; P < .001),
schizophrenia (aHR, 0.73; 95% CI, 0.69-0.77; P < .001), and NAP (aHR, 0.85; 95% CI,
0.79-0.92; P < .001), and self-harmwas reduced in BPD (aHR, 0.73; 95% CI, 0.62-0.84;
P < .001) and schizophrenia (aHR, 0.64; 95% CI, 0.48-0.85; P < .001).
CONCLUSIONS AND RELEVANCE This study provides additional evidence that exposure to
HMG-CoA RIs, LTCC antagonists, and biguanides might lead to improved outcomes for
individuals with SMI. Given the well-known adverse event profiles of these agents, they
should be further investigated as repurposed agents for psychiatric symptoms.
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S erious mental illnesses (SMIs), including bipolar disor-der (BPD), schizophrenia, and nonaffective psychoses(NAP), are associatedwith high levels ofmorbidity and
are challenging to treat. Many drugs have been identified as
havingpotential for repurposing in thesedisorders.1,2Wecross-
referenced these drugs with the most commonly prescribed
drugs in the general population.3 We chose to investigate the
following 3 classes of drugs for which we might expect clini-
cal benefit: hydroxylmethyl glutaryl coenzymeAreductase in-
hibitors (HMG-CoA RIs; ie, statins), L-type calcium channel
(LTCC) antagonists (eg, verapamil hydrochloride), and bigu-
anides (eg, metformin hydrochloride).
A recent meta-analysis of statins as adjunctive therapy
for schizophrenia included 6 placebo-controlled randomized
clinical trials (RCTs) and found a reduction in the Positive
and Negative Symptom Scale scores in patients receiving
statins for 12 weeks; however, only 169 received active treat-
ment, and the reduction fell below the threshold considered
clinically meaningful.4 Theorized mechanisms for HMG-CoA
RI psychiatric action are via anti-inflammatory effects or via
increased absorption and central nervous system uptake of
antipsychotics.4 A systematic review and meta-analysis of
LTCC antagonists for the treatment of BPD5 included 2 RCTs
of verapamil vs placebo and 4 of verapamil vs lithium for the
treatment of mania. The investigators found no evidence of
an effect. However, no trials of other LTCC antagonists and
no studies in BPD depression or prophylaxis have been per-
formed. Evidence of calcium dysregulation in BPD has long
been available; this evidence is supported by more recent
pharmacologic, genetic, and molecular findings.6 Similarly,
calcium signaling is implicated in the etiology of schizophre-
nia, where LTCC antagonists are also a potential adjuvant
treatment.7 However, very limited and inconsistent trial evi-
dence for their use in this disorder exists.8 A trial of metfor-
min has been undertaken to counter antipsychotic-related
weight gain,9 but metformin is also hypothesized to improve
cognitive and mood dysfunction symptoms via mitigation of
metabolic disturbances.10 Therefore, although none of these
drugs have been comprehensively investigated as repur-
posed agents to improve mental disorders, each has a theo-
retical basis for effectiveness.
We investigated whether people in the Swedish popula-
tion with SMI had lower rates of psychiatric hospitalization
and self-harm during periods when they were prescribed
HMG-CoA RIs, LTCC antagonists, and biguanides. Owing
to the risks of confounding by indication, we used a design
that compared within-individual periods with and without
medication exposure,11 which controls for time-fixed con-
founders. In view of the proposed mechanism of action
of each drug on psychiatric symptoms, we hypothesized
that effects would be similar across SMI subtypes. We
also examined rates of nonpsychiatric hospitalization in
these groups and hypothesized that, contrary to psychiatric
effects, nonpsychiatric hospitalizations would only be
reduced in the group exposed to biguanides because these
agents have an acute physical effect, whereas HMG-CoA RIs
and LTCC antagonists have a longer-term mechanism of
action.
Methods
Study Population
Wecollecteddata fromnational registersofSweden fromJanu-
ary1,1973,untilDecember31,2016.Forthepurposeofthisstudy,
theTotalPopulationRegister,MigrationRegister,CauseofDeath
Register, PrescribedDrugRegister, andNational Patient Regis-
terswere linked.ThePrescribedDrugRegister containsdataon
allprescriptionscollected fromJuly 1, 2005,onward (excluding
over-the-countermedicationsanddrugsusedinhospitals).3The
National PatientRegisters contain inpatient records from1964
onward and outpatient records from 2001 onward. These reg-
isters contain sociodemographic and medical information on
each residentofSweden.Ethical approval for thestudywasob-
tainedviatheRegionalEthicalReviewBoardinStockholm,Swe-
den,whichwaived the need for informed consent.
Definition of SMI
We defined diagnoses of BPD, schizophrenia, and NAP in
line with previous research using Swedish National Patient
Registers.12,13 Individuals had at least 1 record of inpatient or
outpatient contact with codes from the International Classi-
fication of Diseases, Ninth Revision (ICD-9) and International
Statistical Classification of Diseases and Related Health Prob-
lems, Tenth Revision (ICD-10) consistent with the diagnosis
(eTable 1 in the Supplement) and a period of drug treatment
with an appropriate psychotropicmedication (antipsychotic,
lithium, or anticonvulsant class mood stabilizer) from Octo-
ber 1, 2005, through December 31, 2016. Validation studies
suggest thatusing inpatient SMIdiagnosis alonehashighposi-
tivepredictivepower (0.94)butpotentiallymisses suitablepa-
tientsowing to type II error (negativepredictivepower, 0.23).14
Exposure to StudyMedications
Themain exposure was defined as treatment with HMG-CoA
RIs, LTCC antagonists, or biguanides (eTable 2 in the Supple-
ment) in the Prescribed Drug Register. In routine practice in
Key Points
Question Are drugs in common use for physical health problems
(hydroxylmethyl glutaryl coenzyme A reductase inhibitors, L-type
calcium channel antagonists, and biguanides) associated with
reduced rates of psychiatric hospitalization and self-harm in
individuals with serious mental illness?
Findings In this series of within-individual cohort studies
of 142 691 patients with bipolar disorder, schizophrenia, or
nonaffective psychosis, exposure to any of the study drugs was
associated with reduced rates of psychiatric hospitalizaiton
compared with unexposed periods. Self-harmwas reduced in
patients with bipolar disorder and schizophrenia during exposure
to all study drugs and in patients with nonaffective psychosis
taking L-type calcium channel antagonists.
Meaning Hydroxylmethyl glutaryl coenzyme A reductase
inhibitors, L-type calcium channel antagonists, and biguanides
hold potential as repurposed agents in serious mental illness, and
the central nervous systemmechanism of action of these drugs
requires further investigation.
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Sweden, oralmedications are rarelydispensed for longer than
3 months at a time. In line with previous studies, we defined
a medication period as a sequence of at least 2 prescriptions,
withnomore than3months (93days) betweenany2 consecu-
tive prescriptions.15,16 Therefore, individualswere defined as
exposed to medication during the interval between 2 dis-
pensed prescriptions unless the dispensed prescriptions oc-
curred more than 3 months apart. To determine whether an
individualwas exposed or nonexposed to themedication ini-
tially, the follow-up start was set to October 1, 2005, because
the coverage of the PrescribedDrugRegister started on July 1,
2005.
Outcomes
Outcomeswerepsychiatrichospitalization (identifiedbyward
admissioncodes and ICD-9and ICD-10 codes for admission in-
dication) and self-harm (with suicidal and undetermined in-
tent) (eTable 1 in the Supplement).We also examined rates of
nonpsychiatric hospitalization. Outcome data came from the
National Patient Register.
Time-Varying Confounders
As a result of the within-individual design, time-fixed covar-
iates (eg, sex, age at illness onset) cannot confound any asso-
ciation between the study drug and the outcome of interest.
Time-varying confounders were included to capture the po-
tential for changes inpsychiatric symptomsover time, includ-
ing age, year, number of previous outcome events (ie, hospi-
talizations, episodes of self-harm), exposure to psychiatric
medication (ie,mood stabilizer or antipsychotic), and a count
of exposed and nonexposed periods.
Statistical Analysis
Data were analyzed fromApril 1 through August 31, 2018.We
performedwithin-individual analysesusing stratifiedCoxpro-
portional hazards regression. This method, by design, exclu-
sively draws information from individuals who ever experi-
enced the outcome of interest during follow-up.17 Therefore,
a different cohort is identified and analyzed for each combi-
nationofdrugexposure andoutcome.Wesplit follow-up time
into consecutive periods. A new period started after a medi-
cation switch (ie, starting and stoppingmedication) or anout-
come event (after the date of discharge). For the latter, we re-
started theperiodat baseline (ie, the timesince the last event).
Drug treatments were defined as time-varying dichotomous
exposures. We estimated adjusted hazard ratios (aHRs) and
95%CIs for differences in outcome event rate betweenmedi-
cation exposure and nonexposure periods; 2-sided P values
were calculated usingWald tests.
Additional Analyses
We tested for an interaction between HMG-CoA RI and anti-
psychotic medication exposure, because of the theory that
HMG-CoA RIs may increase uptake of antipsychotics by the
central nervous system.4We thenperformed several sensitiv-
ity analyses. First, we examined differences in rates of the 3
outcomes in periods that patients with SMI were exposed or
not exposed to thiazide diuretics. We chose this class of drug
as a negative control; no evidence suggests that exposure to
thiazide diuretics should improve psychiatric outcomes, so
lower ratesduringexposedperiodsmight suggest that stability
of SMI symptoms is associatedwithaperiodofmedicationad-
herence rather than a direct effect of the medication on psy-
chiatric symptoms (ie, reverse causality). Second,weadjusted
for time with and without each of the other study drugs and
physical health problems experienced by the individual (car-
diovascular or cerebrovascular disease, type 2 diabetes, hy-
pertension, andhyperlipidemia). Third,weexcluded fromthe
analysis individuals who died during the follow-up period
because theymayhave amore rapidly varying risk of the out-
comes of interest. Fourth, we excluded psychiatric admis-
sions, which were prompted by admissions for self-harm
(ie, a psychiatric admission in the 7 days after a self-harm ad-
mission), to examine whether self-harm and psychiatric ad-
missions were independent. Finally, we extended the defini-
tion of the drug exposure period and defined it as constant if
a new prescription was issued within 4 months (124 days) of
the previous prescription and extended the exposure period
to 2months (62 days) after the last dispensed date to account
forpotentialexposuremisclassification inourprimaryanalysis.
Results
These studiesdrew fromtheentirepopulationof Swedenwho
ever received an inpatient or outpatient diagnosis of SMI and
were treated with an antipsychotic or mood stabilizer medi-
cation from October 1, 2005, through December 31, 2016
(eFigure in the Supplement). This base population included
76 759 patients with BPD, 30 954 with schizophrenia, and
34978 with NAP for a total of 142691 patients.
HMG-CoA Reductase Inhibitors
Of the patients described above, 6176 with BPD (3493 female
[56.6%] and 2683 male [43.4%]; mean [SD] age, 55.3 [12.3]
years), 2705with schizophrenia (1084 female [40.1%]and 1621
male [59.9%];mean [SD] age, 49.6 [12.6] years), and2958with
NAP (1603 female [54.2%] and 1355male [45.8%]; mean [SD]
age, 57.8 [15.0] years) were also prescribedHMG-CoARIs and
experienced psychiatric hospitalization (Table 1). All sub-
groups of SMI had reduced rates of psychiatric hospitaliza-
tionduringHMG-CoARIexposureafter adjusting for age, year,
number of previous hospitalizations, psychiatric medication
exposure, andnumberof exposureperiods (aHR forBPD,0.86
[95% CI, 0.83-0.89]; aHR for schizophrenia, 0.75 [95% CI,
0.71-0.79]; andaHRforNAP,0.80 [95%CI,0.75-0.85];P < .001
for all). Individuals with BPD (aHR, 0.76; 95% CI, 0.66-0.86;
P < .001) or schizophrenia diagnoses (aHR, 0.58; 95% CI,
0.45-0.74;P < .001) had lower rates of self-harmduringHMG-
CoA RI exposure periods compared with nonexposure peri-
ods (Table 2; eTable 3 in the Supplement). Exposure status for
HMG-CoA RIs was not associated with nonpsychiatric hospi-
talization, apart from in theNAPsubgroup (aHR, 1.04; 95%CI,
1.01-1.08; P = .02) (Table 2; eTable 4 in the Supplement). We
found no evidence of an interaction between HMG-CoA
RI and antipsychotic exposure. Adjustment for additional
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time-varying confounders, such as LTCCantagonist andbigu-
anideexposure,cardiovascularorcerebrovasculardisease, type
2 diabetes, hypertension, and hyperlipidemia, did not affect
the results for psychiatric hospitalization or self-harm out-
comes, but nonpsychiatric hospitalization rates were signifi-
cantly reduced during HMG-CoA RI exposure periods (aHR,
0.73; 95%CI,0.72-0.74;P < .001) (Table 3). Excludingpatients
who died during follow-up did not change results for rates of
psychiatric hospitalization or self-harm, but HMG-CoA RI
exposure periods became associated with increased rates of
nonpsychiatric hospitalization (aHR, 1.08; 95% CI, 1.06-1.11;
P < .001). After excluding psychiatric hospitalizations
promptedby self-harm, the associationbetweenHMG-CoARI
exposure periods and psychiatric hospitalization remained
similar (aHR, 0.82; 95% CI, 0.80-0.84; P < .001). Redefining
exposure period as constant for less than 4 months between
prescriptions and extending to 2 months after the last pre-
scription date did not change the findings.
LTCC Antagonists
Ofthosemeeting inclusioncriteriaandprescribedLTCCantago-
nists, 4636 with BPD (2676 female [57.7%] and 1960 male
[42.3%];mean[SD]age,56.1 [13.5]years), 1581withschizophre-
nia (701 female [44.3%] and 880male [55.7%];mean [SD] age,
54.2 [12.1] years), and2337withNAP (1406 female [60.2%]and
931male [39.8%];mean[SD]age,60.9 [15.4]years)experienced
psychiatrichospitalization (Table 1).DuringperiodsofLTCCan-
tagonistexposure,allgroupshadreducedpsychiatricadmissions
(aHRforBPD,0.92[95%CI,0.88-0.96;P < .001];aHRforschizo-
phrenia, 0.80 [95% CI, 0.74-0.85; P < .001]; and aHR for NAP,
0.89[95%CI,0.83-0.96;P = .002])andreducedself-harmevents
(aHR forBPD,0.81 [95%CI,0.68-0.95;P = .01]; aHR for schizo-
phrenia, 0.30 [95%CI, 0.18-0.48; P < .001]; aHR for NAP, 0.56
[95%CI,0.42-0.74;P < .001]) (Table2andeTable3intheSupple-
ment).ExposuretoLTCCantagonistswasnotassociatedwiththe
nonpsychiatrichospitalizationrate(eTable4intheSupplement).
Additional adjustment for the other study drugs and physical
healthproblemsdidnotaffect thepsychiatrichospitalizationor
self-harm results, but nonpsychiatric admissions were signifi-
cantly reduced during LTCC antagonist exposure (aHR, 0.95;
95% CI, 0.93-0.97; P < .001) (Table 3). Excluding patients who
diedsuggestedanincreasedrateofnonpsychiatricadmissiondur-
ing LTCC antagonist exposure (aHR, 1.09; 95% CI, 1.06-1.12;
P < .001). Excluding psychiatric admissions prompted by self-
harmdidnotalter theassociation (aHRforall SMI,0.86;95%CI,
0.83-0.88; P < .001). Redefining the drug exposure period did
not alter our findings.
Biguanides
In total, 7349patientswereexposed tometforminandhadpsy-
chiatric hospitalizations during follow-up, ofwhom3493had
BPD (1998 female [57.2%] and 1495male [42.8%]; mean [SD]
age, 50.5 [14.4] years), 2294 had schizophrenia (974 female
[42.4%] and 1320 male [57.5%]; mean [SD] age, 47.2 [13.2]
Table 2. Psychiatric Hospitalization, Self-harm, and Nonpsychiatric Hospitalization During Drug Exposure vs Nonexposure Periods
SMI
Outcome, HR (95% CI)
Psychiatric Hospitalization Self-harm Nonpsychiatric Hospitalization
Unadjusted Adjusteda Unadjusted Adjusteda Unadjusted Adjusteda
HMG-CoA Reductase Inhibitors
BPD 0.81 (0.79-0.84) 0.86 (0.83-0.89) 0.76 (0.67-0.85) 0.76 (0.66-0.86) 1.01 (0.98-1.03) 1.00 (0.98-1.03)
P value <.001 <.001 <.001 <.001 .64 .49
Schizophrenia 0.74 (0.71-0.78) 0.75 (0.71-0.79) 0.64 (0.51-0.81) 0.58 (0.45-0.74) 1.08 (1.03-1.12) 1.03 (0.99-1.08)
P value <.001 <.001 <.001 <.001 <.001 .13
NAP 0.79 (0.75-0.83) 0.80 (0.75-0.85) 0.93 (0.78-1.12) 0.86 (0.71-1.05) 0.98 (0.94-1.01) 1.04 (1.01-1.08)
P value <.001 <.001 .45 .15 .13 .02
LTCC Antagonists
BPD 0.82 (0.79-0.85) 0.92 (0.88-0.96) 0.81 (0.70-0.95) 0.81 (0.68-0.95) 1.03 (1.00-1.06) 1.01 (0.98-1.04)
P value <.001 <.001 .007 .01 .01 .66
Schizophrenia 0.78 (0.73-0.83) 0.80 (0.74-0.85) 0.49 (0.32-0.77) 0.30 (0.18-0.48) 1.04 (1.00-1.10) 1.03 (0.98-1.08)
P value <.001 <.001 .002 <.001 .08 .20
NAP 0.78 (0.73-0.83) 0.89 (0.83-0.96) 0.81 (0.63-1.04) 0.56 (0.42-0.74) 0.96 (0.92-0.99) 0.97 (0.93-1.01)
P value <.001 .002 .10 <.001 .02 .13
Biguanides
BPD 0.69 (0.67-0.72) 0.80 (0.77-0.84) 0.74 (0.65-0.84) 0.73 (0.62-0.84) 0.86 (0.83-0.90) 0.84 (0.81-0.87)
P value <.001 <.001 <.001 <.001 <.001 <.001
Schizophrenia 0.59 (0.56-0.63) 0.73 (0.69-0.77) 0.70 (0.55-0.90) 0.64 (0.48-0.85) 0.91 (0.87-0.96) 0.84 (0.80-0.89)
P value <.001 <.001 .005 <.001 <.001 <.001
NAP 0.66 (0.61-0.71) 0.85 (0.79-0.92) 0.82 (0.66-1.02) 0.91 (0.71-1.16) 0.85 (0.80-0.89) 0.85 (0.80-0.90)
P value <.001 <.001 .08 .44 <.001 <.001
Abbreviations: BPD, bipolar disorder; HMG-CoA, hydroxylmethyl glutaryl
coenzyme A; HR, hazard ratio; LTCC, L-type calcium channel; NAP, nonaffective
psychosis; SMI, serious mental illness.
a Adjusted for time-varying covariates, including age, year, number of previous
outcome events, and psychiatric medication exposure (antipsychotic, lithium,
or anticonvulsant mood stabilizer).
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years), and 1562 had NAP (839 female [53.7%] and 723 male
[46.3%]; mean [SD] age, 50.5 [16.4] years) (Table 1). All sub-
groupshad similarly reducedpsychiatric hospitalization rates
during metformin exposed compared with unexposed peri-
ods (aHR for BPD, 0.80 [95%CI, 0.77-0.84; P < .001]; aHR for
schizophrenia, 0.73 [95%CI, 0.69-0.77;P < .001]; andaHR for
NAP, 0.85 [95% CI, 0.79-0.92; P < .001]). Self-harm was re-
duced in theBPD (aHR,0.73; 95%CI, 0.62-0.84;P < .001) and
schizophrenia (aHR, 0.64; 95% CI, 0.48-0.85; P < .001) sub-
groups (Table 2 andeTable 3 in the Supplement). Across all di-
agnostic groups,metformin exposurewas associatedwith re-
duced rates of nonpsychiatric hospitalization (aHR for BPD,
0.84 [95%CI,0.81-0.87]; aHR for schizophrenia,0.84 [95%CI,
0.80-0.89]; and aHR for NAP, 0.85 [95% CI, 0.80-0.90];
P < .001 for all) (eTable 4 in the Supplement). Additional ad-
justment for the other study drugs and physical health prob-
lems, exclusion of those who died during follow-up, and re-
defining theexposureperioddidnotaffect the results (Table3),
nor did exclusion of psychiatric admissions in the 7 days after
self-harm (aHR, 0.79; 95% CI, 0.77-0.81; P < .001).
Thiazide Diuretics
Noevidence suggested that thiazidediuretic exposurewas as-
sociated with psychiatric hospitalization (aHR, 0.99; 95% CI,
0.93-1.05; P = .64) or self-harm (aHR, 0.94; 95%CI, 0.75-1.19;
P = .61).However, exposurewasassociatedwitha reduced rate
of nonpsychiatric admissions (aHR, 0.92; 95% CI, 0.88-0.96;
P < .001) (Table 3 and eTable 5 in the Supplement).
Discussion
As far aswe are aware, this study is the first to suggest that pe-
riodsofexposure toHMG-CoARIs,LTCCantagonists, andbigu-
anides are associatedwith lower ratesofpsychiatric admission
and self-harm in patients with SMI. Each of these drugs has a
theoreticalbasis foreffectively reducingpsychiatric symptoms.
We found thatperiodsofHMG-CoARIexposurewereasso-
ciatedwith reducedpsychiatrichospitalization inall subgroups
ofSMIandwithreducedself-harminBPDandschizophrenia.Sev-
eral actionsofHMG-CoARIs couldexplainour findings. Statins
Table 3. Additional Analyses of Psychiatric Hospitalization, Self-harm, and Nonpsychiatric Hospitalization
During Drug Exposure vs Nonexposure Periods
Study Drug
Outcome, HR (95% CI)a
Psychiatric Hospitalization Self-harm Nonpsychiatric Hospitalization
Negative control
Thiazide diuretics 0.99 (0.93-1.05) 0.94
(0.75-1.19)
0.92 (0.88-0.96)
P value .64 .61 <.001
Additionally Adjusted for Other Study Drugs and Physical Health Problemsb
HMG-CoA reductase inhibitors 0.81 (0.79-0.84) 0.75
(0.67-0.83)
0.73 (0.72-0.74)
P value <.001 <.001 <.001
LTCC antagonists 0.87 (0.84-0.90) 0.69
(0.60-0.79)
0.95 (0.93-0.97)
P value <.001 <.001 <.001
Biguanides 0.68 (0.66-0.71) 0.72
(0.63-0.82)
0.76 (0.74-0.78)
P value <.001 <.001 <.001
Excluding Individuals Who Died During Follow-up
HMG-CoA reductase inhibitors 0.83 (0.80-0.85) 0.75
(0.67-0.85)
1.08 (1.06-1.11)
P value <.001 <.001 <.001
LTCC antagonists 0.89 (0.86-0.92) 0.75
(0.64-0.88)
1.09 (1.06-1.12)
P value <.001 <.001 <.001
Biguanides 0.77 (0.75-0.80) 0.73
(9.64-0.83)
0.91 (0.88-0.94)
P value <.001 <.001 <.001
Exposure Is Constant if 4 mo Between Prescriptions and Ends 2 mo After Final Prescription
HMG-CoA reductase inhibitors 0.80 (0.78-0.82) 0.76
(0.69-0.84)
1.00 (0.99-1.02)
P value <.001 <.001 .71
LTCC antagonists 0.91 (0.88-0.94) 0.69
(0.61-0.79)
1.02 (1.00-1.04)
P value <.001 <.001 .02
Biguanides 0.83 (0.81-0.86) 0.74
(0.66-0.83)
0.93 (0.91-0.95)
P value <.001 <.001 <.001
Abbreviations: BPD, bipolar disorder;
HMG-CoA, hydroxylmethyl glutaryl
coenzyme A; HR, hazard ratio;
LTCC, L-type calcium channel;
NAP, nonaffective psychosis.
a Adjusted for time-varying
covariates, including age, year,
number of previous outcome
events, and psychiatric medication
exposure (antipsychotic, lithium,
and anticonvulsant mood stabilizer).
bAdditionally adjusted for calcium
channel antagonist, HMG-CoA
reductase inhibitor, and biguanides
exposure periods, cardiovascular
or cerebrovascular disease
diagnosis, type 2 diabetes mellitus,
hypertension, and hyperlipidemia.
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are anti-inflammatory, with effects on levels of interleukin-1β,
interleukin-6, tumornecrosis factor, andC-reactiveprotein.18,19
Extensiveevidencesuggests thatsystemicandneuroinflamma-
toryprocessesare involved in thepathophysiologyofpsychiat-
ricdisorders.4Alternatively(orsynergistically),HMG-CoARIsmay
interactwith other substrates for P-glycoprotein (including an-
tipsychoticmedications).We found no evidence of interaction
betweenperiodsofstatinandantipsychoticexposureinourstudy.
However,toassessthismechanism,wewouldneedtospecifically
examinedrugswithahighaffinityforP-glycoprotein,suchasque-
tiapine fumarateor risperidone.20The lownumberof events in
thoseexposedtospecificantipsychoticspreventedrobustanaly-
sis.Inaddition,animalmodelshavefoundthatstatinsup-regulate
N-methyl-D-aspartatereceptors21andincreasemuscarinicrecep-
torbinding,22potentiallyproducingneuroprotectiveeffects,and
increasedopamine receptor levels centrally,23potentially caus-
ing antipsychotic effects. Anyof thesemechanismsmay reflect
the relatively acute effect of statins on rates of psychiatric hos-
pitalizationandself-harmthatweobserve.Incontrast,themecha-
nismfor treatmentofhypercholesterolemia is slower, involving
inhibitionofHMG-CoAreductase,a resultant reduction inhepa-
tocyte cholesterol level, and an increase of hepatic low-density
lipoprotein receptor levels,which clear circulating low-density
lipoprotein and its precursors.24
Exposure to LTCC antagonists was associated with re-
duced rates of psychiatric hospitalization and self-harm. The
LTCCshavebeen implicated in thephysiopathologyof a range
of mental health conditions, including mood disorders, ad-
diction, dementia, sleepdisorders,6 andpsychotic illness.7 In-
hibition of LTCCs has cardiodepressant and vasodilatory ac-
tions, but isoformsofLTCCsarewidelydistributedbeyond the
cardiovascular system, including neurons.25 These isoforms
appear to control emotionalbehavior inanimalmodels andare
associated with antidepressant and anxiolytic effects.25
Periods of metformin exposure were associated with re-
ducedpsychiatric andnonpsychiatrichospitalizationacrossall
SMIsubgroups.Self-harmwas reduced in individualswithBPD
and schizophreniaduringbiguanide exposure.Metforminhas
been widely investigated in psychiatry because of its poten-
tial to attenuate antipsychotic-induced weight gain, includ-
ing in patientswithout diabetes.26 Unfortunately, these trials
didnot routinely report changes inpsychiatric symptoms.Met-
forminmay potentially improve symptoms in SMI because of
underlying disturbed cerebral use of glucose, particularly in
brainareas linked tocognitive impairments in schizophrenia.27
Hypercholesterolemia,hypertension,diabetes, andpredia-
betes aremore common inpeoplewith SMI, and evidence sug-
gests that they are not as rigorously treated as in the general
population.28Our findingsnotwithstanding,moreeffort should
bemadetoprescribethesedrugswhenindividualswithSMIfulfill
establishedclinicalcriteria for theiruse. Inaddition,useof these
medicationswithinclinicalguidelines isalreadybroader than in
thegeneralpopulation.Forexample,astatinwillbe indicated in
anymanolder than60yearswith SMI, but noother risk factors
for cardiovascular disease, according to risk calculators,29,30
andadjunctivemetformin therapy is recommended tomanage
antipsychotic-associatedweightgain.28All3classeshaverelatively
good adverse event profiles.31-33 Ideally, further RCTs of these
drugs will be conducted that are appropriately powered, with
meaningful clinical endpoints.
Strengths and Limitations
ComparedwithpossibleRCTs,our large,population-based lon-
gitudinal sampleavoids selectionbiasbecause itpotentially in-
cludesall individuals. InRCTs,recruitingrepresentativesamples,
suchasactivelysuicidalparticipantsorthosewhoareacutelyun-
well, ismorechallenging.Ourstudyisthereforepotentiallymore
generalizableandrepresentative.However, tobe includedinthe
study, individualshadtobeprescribedastudydrug, suggesting
poorphysicalhealth,andexperienceat least1outcome,suggest-
ing poor mental health. We therefore potentially included the
mostunwell individuals. Inaddition,mostindividualswereolder
than50yearsat thestartof follow-up,sosurvivalbias ispossible.
WhetherourresultsgeneralizetothewiderpopulationwithSMI
remainsunclear,but thegroupstudiedwouldusuallybeconsid-
eredmostdifficult to treat.Thecomparisonofexposedandun-
exposedperiodswithin thesame individual automatically con-
trols for time-invariant confounders, reducing the likelihoodof
confoundingbyindication.Wethenadditionallyadjustedforpo-
tentially important time-varyingconfounders.However,aswith
otherobservationaldesigns,wecannotruleoutresidualandun-
measured time-varying confounding. In particular, confound-
ingmay be linked to varying severity of SMI symptoms.We at-
tempted to investigate whether periods of symptom stability
were associatedwith adherence to any prescribedmedication
anda reduced rateofpsychiatrichospitalizationandself-harm
byexaminingnonpsychiatrichospitalizationratesandbystudy-
ing a drug class that should have no effect on psychiatric out-
comes.Nonpsychiatrichospitalizationwasnotassociatedwith
HMG-CoARI or LTCC antagonist exposure periods, suggesting
noglobal effectonhealth serviceuse.Theeffects seemspecific
to psychiatric outcomes. Biguanide exposurewasprobably as-
sociatedwith reduced nonpsychiatric hospitalization because
this classofmedicationhasmoreacuteeffects.Thiazidediuret-
ics, a groupofmedications that haveno theorizedbasis for im-
proving psychiatric symptoms, were not associatedwith rates
ofpsychiatrichospitalizationor self-harmratebutwereassoci-
atedwith reduced ratesofnonpsychiatrichospitalization.This
findingsuggests thatmedicationadherence inandof itself isnot
aproxyformental statestability,whichwouldbereflected inre-
duced rates of psychiatric hospitalization and self-harm.
Exposuremisclassification isapotential risk; inourprimary
analysis, patients were considered unexposed after the date of
their lastprescription.This classificationpotentiallyunderesti-
mates exposure timebutwould bias estimates toward thenull.
In the sensitivity analysis with increased exposure time, effect
estimateswerecomparable.Unfortunately, thePrescribedDrug
Registerdoesnot include informationondoseanddays supply.
Similarly,welackdirect informationontreatmentadherenceand
definedpatients collecting2ormoreprescriptionsasadherent.
Nonadherencewouldmeanourreportedassociationsrepresent
underestimates of the true effect. Misclassification of SMI
subgroupispossible,butgiventheinclusioncriteriaforthisstudy,
we were unlikely to include patients who do not have some
formofSMI.14,34,35Self-harmthatdidnotresult inhospitalatten-
dance is not captured by our study.
Repurposing HMG-CoA Reductase Inhibitors, L-Type Calcium Channel Antagonists, and Biguanides for Serious Mental Illness Original Investigation Research
jamapsychiatry.com (Reprinted) JAMAPsychiatry Published online January 9, 2019 E7
Downloaded From:  by a University College London User  on 01/14/2019
Conclusions
If substantiated, this study has considerable implications for
clinical practice and drug development. The study drugs—
HMG-CoA RIs, LTCC antagonists, and biguanides—are glob-
ally licensed, commonlyused, cheap, and relatively safemedi-
cations. They are therefore ideal candidates for repurposing.
Understanding their mode of action on the central nervous
systemmay facilitate better understandingof thepathophysi-
ology of SMI and offer opportunities for innovative pharma-
cotherapy development.
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